Skip to main content

Multiple System Atrophy clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for
  • North American Prodromal Synucleinopathy Consortium

    open to eligible people ages 18 years and up

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • Trial of Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UC Davis UC Irvine UCLA UCSF

  • GDNF Gene Therapy for Multiple System Atrophy

    Sorry, not yet accepting patients

    The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.

    at UC Irvine UCSD

  • Study of BHV-3241 in Subjects With Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to compare the efficacy of BHV-3241 versus placebo in subjects with Multiple System Atrophy

    at UCLA UCSD UCSF

Last updated: